<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In acquired <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo>, B-cell proliferation is usually associated with Epstein-Barr virus (EBV), implying the impairment of the <z:mpath ids='MPATH_458'>normal</z:mpath> control of EBV and EBV-infected cells </plain></SENT>
<SENT sid="1" pm="."><plain>It has been assumed that <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> is latent in <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In order to determine the type of latency and to investigate whether any <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> enter into the lytic cycle, we analyzed the expression of latent and replicative EBV genes in 9 post-transplant <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> (PTLD) and in 23 EBV-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-related non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (AR-NHL) </plain></SENT>
<SENT sid="3" pm="."><plain>The PTLD cases were categorized into polyclonal or monoclonal polymorphic <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and monoclonal monomorphic <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The AR-NHL cases included large-cell/<z:e sem="disease" ids="C1521815" disease_type="Neoplastic Process" abbrv="">immunoblastic</z:e> (LC/IB) and Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) groups </plain></SENT>
<SENT sid="5" pm="."><plain>We demonstrated that varying patterns of latent-<z:mp ids='MP_0001799'>viral</z:mp>-gene expression are exhibited showing the 3 forms of latency </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C1301361" disease_type="Neoplastic Process" abbrv="">Polymorphic PTLD</z:e> and LC/IB AR-NHL frequently expressed type II or III latency, whereas monomorphic <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> AR-NHL showed type I latency </plain></SENT>
<SENT sid="7" pm="."><plain>It is noteworthy that 3 cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> AR-NHL expressed latency II form </plain></SENT>
<SENT sid="8" pm="."><plain>Induction of lytic cycle highlighted by the expression of BZLF1 occurred in 55.5% of PTLD, 36% of LC/IB and 22% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> AR-NHL </plain></SENT>
<SENT sid="9" pm="."><plain>In contrast, late <z:mp ids='MP_0001799'>viral</z:mp> proteins indicating productive cycle were present in 22% of PTLD, 14% of LC/IB, and were absent in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cases </plain></SENT>
<SENT sid="10" pm="."><plain>These data suggest that the impairment of EBV control permits disruption of latency, but the initiation of the lytic cycle may not always lead to <z:mp ids='MP_0001799'>viral</z:mp> production </plain></SENT>
</text></document>